原著論文Original Articles

2021年

ワクチン創成グループ 

  1. Tamiya S, Yoshikawa E, Suzuki K, Yoshioka Y. Susceptibility analysis in several mouse strains reveals robust T-cell responses after Mycoplasma pneumoniae infection in DBA/2 mice. Front Cell Infect Microbiol. 2021 Jan 13;10:602453.
  2. Shibuya M, Tamiya S, Kawai A, Yoshioka Y. Nasal–subcutaneous prime–boost regimen for inactivated whole-virus influenza vaccine efficiently protects mice against both upper and lower respiratory tract infections. Biochem Biophys Res Commun. 2021 May 21;554:166-172.
  3. Kashio T, Shirakura K, Kinoshita M, Morita M, Ishiba R, Muraoka K, Kanbara T, Tanaka M, Funatsu R, Hino N, Koyama S, Suzuki R, Yoshioka Y, Aoshi T, Doi T, Okada Y. HDAC inhibitor, MS-275, increases vascular permeability by suppressing Robo4 expression in endothelial cells. Tissue Barriers. 2021 May 6:1911195.
  4. Kawai A, Yamamoto Y, Nogimori T, Takeshita K, Yamamoto T, Yoshioka Y. The potential of neuraminidase as an antigen for nasal vaccines to increase cross-protection against influenza viruses. J Virol. 2021 Aug 11;JVI0118021.

ウイルスワクチングループ 

  1. Suzuki H, Noguchi T, Ogawa K, Miyazato P, Hatakeyama Y, Morita E, Ebina H. Fusion of parvovirus B19 receptor-binding domain and pneumococcal surface protein A induces protective immunity against parvovirus B19 and Streptococcus pneumoniae. Vaccine. 2021 Aug 23; 39(36):5146-5152.
  2. Okamura S, Ebina H. Could live attenuated vaccines better control COVID-19? Vaccine. 2021 Aug 11: S0264-410X(21)01038-0.
  3. Kimura S, Maeda K, Nagashima R, Miura K, Arakawa M, Ebina H, Tanaka N, Morita E. Efficient immunogenic peptide antigen delivery to dendritic cells using an ESCRT-mediated extracellular vesicle formation method. Vaccine. 2021 May 21; 39(22):2976-2982.
  4. Okamura S, Kashiwabara A, Suzuki H, Ueno S, Miyazato P, Takekawa S, Kamitani Y, Yamanishi K, Ebina H. Live attenuated SARS-CoV-2 vaccine candidate: Protective immunity without serious lung lesions in Syrian hamsters. bioRxiv. 2021 Feb 15; 430863.
TOP